Lncrna NEAT1 Regulates Th1/Th2 in Pediatric Asthma by Targeting MicroRNA-217/GATA3.

Background: The imbalance of immune response between helper Th1 and Th2 cells is the direct cause of asthma. It was closely related to abnormal expression of lncRNAs. However, whether lncRNAs can regulate Th1/Th2 balance in pediatric asthma remains to be investigated. Methods: Peripheral blood samples were collected from children with asthma and normal volunteers at the Children's Hospital of Shaanxi Provincial People's Hospital (Xi'an, China) in 2020. The qRT-PCR was used to detect the expression of lncRNA NEAT1, miR-217 and GATA3 in peripheral blood samples. The effects of lncRNA NEAT1, miR-217, and GATA3 on CD4+T cell population were detected in vitro. Meanwhile, the regulatory effect of lncRNA NEAT1/miR-217/GATA3 was evaluated through the dual luciferase report assay, functional assays and animal experiments. Results: We investigated that lncRNA NEAT1 and GATA3 was significantly up-regulated in CD4+T cells in peripheral blood of children with asthma (P<0.001). Knockdown of lncRNA NEAT1 or GATA3 significantly reduced Th2-related cytokines (P<0.05), but had no effect on Th1 cells. Importantly, the interactions of lncRNA NEAT1 with miR-217 and miR-217 with GATA3 were confirmed by dual luciferase report assay. Meanwhile, functional assays and animal experiments demonstrated that lncRNA NEAT1 regulated GATA3 expression through sponge miR-217, thereby regulating Th1/Th2 balance in CD4+T cells in pediatric asthma. Conclusion: lncRNA NEAT1/miR-217/GATA3 axis may reveal the immunological mechanism of pediatric asthma, which has potential clinical application value in the future.

[Clinical experience in the treatment of incomplete Kawasaki disease with no response to intravenous immunoglobulin: a case report]. / é™è„‰æ³¨å°„å ç–«çƒè›‹ç™½æ— åº”ç­”ä¸å®Œå ¨æ€§å·å´Žç— 1例临床经验交流.

This article reports a case of incomplete Kawasaki disease with no response to intravenous immunoglobulin (IVIG). A girl, aged 1 year, had the symptoms of fever, rash, finger desquamation, and coronary artery ectasia. She still had fever at 36 hours after the first dose of IVIG treatment, and her temperature returned to normal after the second dose of IVIG treatment. The follow-up after 1 month showed that the coronary artery diameter returned to normal. This article summarizes the experience in the treatment of incomplete Kawasaki disease with no response to IVIG in order to reduce the incidence of coronary artery damage.

Clinical Profile of COVID-19 in Children and Research Progress on Angiotensin-converting Enzyme 2: A Mini-review.

The cases of coronavirusdisease 2019 in children have been increasing with the ongoing pandemic.The finding suggests children have mild symptoms and a short course of the disease. Angiotensinconverting enzyme-2 mediates entry of the virus into the cell, the combination of virus and ACE2 leads to an increase in activity of angiotensin II, resulting in acute injury to lungs, myocardium and other organs. The infection causes down-regulation of ACE2 expression. The ACE2 plays an important role in the infection progression and clinical characteristics of COVID-19. Works on ACE2 and virus spike protein have future prospects of strategic information on prevention, management as well as vaccine development. Keywords: children;Coronavirus Disease 2019(COVID-19);SARS-Cov-2;angiotensin-Converting Enzyme 2 (ACE2).

Clinical analysis of 102 cases of Epstein-Barr virus infections in Chinese children.

The purpose of this study is to investigate the clinical manifestations and disease severity, to evaluate the recent trend of clinical manifestations and differences in the clinical and laboratory findings of EBV-associated IM (infectious mononucleosis) according to the age of children. We retrospectively collected cases on hospitalized patients a majority of 7 years old with characteristic symptoms of IM and serologically diagnosed EBV-associated IM at Shaanxi Provincial Peoples University Hospital in Xi'an from Apr, 2012 to Oct, 2013. All their medical records were reviewed and analyzed. For each patient, clinical, laboratory data and outcome were collected retrospectively and compared to previous studies to evaluate the differences between the clinical and laboratory findings of patients of different ages. The clinical manifestations in children with EB virus infection varied. There were 60 (58.8%) cases of children with infectious mononucleosis, 26 (25.49%) cases of Epstein-barr virus infection,16 cases of the atypical EB virus infection, accounting for 15.67%. 78% children were under 7 years of age, 12% were 7 to 14 years of age. There are differences in the symptoms and signs among the different age groups. The clinical manifestations in children with EB virus infection involved multiple systems and produced harm is heavier and should be paid attention to during the treatment. The disease continues to occur mostly in children under 10 years of age. When compared to previous Chinese studies about 15 years ago, the age distribution was similar and the incidence of hepatosplenomegaly was lower in our study.